Boston Scientific Corporation
BSXNYSEHealthcare● Active
$48.75
+$0.20(+0.41%)
Market Cap$72.5B
P/E Ratio—
52W High$109.5
52W Low$47.17
Boston Scientific Corporation (BSX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BSX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B |
| Cost of Revenue | $6.22B | $6.48B | $5.41B | $4.97B | $4.43B |
| Gross Profit | $13.85B | $10.27B | $8.83B | $7.71B | $7.46B |
| Gross Margin %(computed) | 69.01% | 61.31% | 62.02% | 60.83% | 62.76% |
| Operating Expenses | |||||
| R&D Expenses | $2.05B | $1.61B | $1.41B | $1.32B | $1.20B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $9.88B | $7.63B | $6.65B | $5.89B | $5.54B |
| Operating Income | $3.97B | $2.63B | $2.18B | $1.82B | $1.92B |
| Operating Margin %(computed) | 19.78% | 15.73% | 15.32% | 14.38% | 16.17% |
| Interest Income | $0.00B | $0.11B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.35B | $0.39B | $0.27B | $0.46B | $0.35B |
| Income Before Tax | $3.38B | $2.28B | $1.99B | $1.14B | $1.08B |
| Income Tax Expense | $0.49B | $0.44B | $0.39B | $0.44B | $0.04B |
| Net Income | $2.89B | $1.85B | $1.59B | $0.70B | $1.04B |
| Net Margin %(computed) | 14.38% | 11.07% | 11.19% | 5.50% | 8.75% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.96 | $1.26 | $1.08 | $0.45 | $0.69 |
| Wtd Avg Shares | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B |
| EBITDA | $3.73B | $3.94B | $3.45B | $2.74B | $2.52B |
| EBITDA Margin %(computed) | 18.60% | 23.51% | 24.25% | 21.61% | 21.18% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Boston Scientific Corporation data
About Boston Scientific Corporation (BSX) Income Statement
Boston Scientific Corporation (BSX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BSX reported revenue of $20.07B, gross profit of $13.85B (gross margin 69.01%), and net income of $2.89B — a net profit margin of 14.38%.
Frequently asked questions
BSX · 4 questionsBoston Scientific Corporation (BSX) reported revenue of $20.07B for 2025, up 19.9% year-over-year.
BSX revenueBSX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08